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2ABSTRACT
Objective: To compare the perioperative outcomes of interventions aiming to decrease
ischemia-reperfusion (IR) injury during elective liver resection.
Method: A comprehensive literature search was performed to identify randomized controlled
trials. A Bayesian network meta-analysis was performed using the Markov chain Monte Carlo
method in WinBUGS following the guidelines of The National Institute for Health and Clinical
Excellence Decision Support Unit. Odds ratios for binary outcomes and mean differences for
continuous outcomes were calculated using fixed-effect model or random-effects model
according to model-fit.
Results: Forty four trials with 2457 patients undergone liver resection were included, and were
divided into eight classes of interventions aimed at decreasing IR injury and a control group
which was surgery alone. There was no significant difference between the different
interventions in mortality, quantity of blood transfusion, and Intensive Therapy Unit stay
between any pairwise comparison. Patients treated with ischemic preconditioning,
cardiovascular modulators, and miscellaneous interventions had significantly fewer serious
adverse events compared to patients receiving surgery alone. Ischemic preconditioning patients
had significantly fewer transfusion proportions and shorter operative time than patients treated
with steroids. Ischemic preconditioning had significantly lower operative blood loss compared
to all other interventions, and shorter length of hospital stay than surgery alone. Sensitivity
analysis showed that the drugs sevoflurane (a volatile anesthetic), verapamil (a calcium channel
blocker), and gabexate mesilate (a thrombin inhibitor) produced fewer serious adverse events
compared to surgery alone.
Conclusion: Ischemic preconditioning resulted in multiple beneficial clinical end points and
further RCTs are needed to confirm its clinical benefits.
3INTRODUCTION
Control of the hepatic blood flow has allowed major hepatectomies to be carried out with
decreased blood loss but it has done so at the expense of liver damage from ischemic-
reperfusion (IR) injury. IR injury is initiated by reactive oxygen species which cause direct
apoptotic and necrotic cell death of hepatocytes and sinusoidal endothelial cells (SEC)1, 2. A
cascade of molecular mediators is activated leading to microvascular and acute inflammatory
changes. Platelet plugging, reduced nitric oxide (NO), and vasoconstrictors lead to sinusoidal
perfusion failure1, 2. Proinflammatory cytokines produced by Kupffer cells result in T-cell and
neutrophil activation and transmigration, resulting in more necrosis and/or apoptosis of SEC
and hepatocytes1, 2.
IR injury results in elevated liver enzymes and increased postoperative morbidity2-6. Patients
with cirrhotic or steatotic liver are more sensitive to IR injury than patients with normal liver3,
6. Many interventions have been used to decrease IR injury 3, 7-22 and previous standard pairwise
meta-analyses comparing these interventions23-25 were limited by the fact that indirect
comparisons between interventions could not be performed. The aim of this network meta-
analysis is to combine direct and indirect evidence across trials in order to compare
perioperative outcomes of different interventions aimed at decreasing IR injury during elective
hepatectomy.
4METHODS
Search strategy
A comprehensive literature search was performed of the following databases: MEDLINE,
EMBASE, Science Citation Index Expanded, Cochrane Central Register of Controlled Trials
(CENTRAL). Detailed search strategy is provided in Supplementary Table 1. No restrictions
were made based on language, publication year, or publication status. Only randomized
controlled trials (RCTs) were considered for inclusion.
Outcomes of interest
Primary outcomes
 Mortality
 Serious adverse events, defined as any event that is life-threatening, requires inpatient
hospitalization, results in a single organ failure (e.g. liver failure) or multi-organ failure, or
requires surgical, endoscopic or radiological intervention to treat it. Serious adverse events
correspond to Grade III or above of the Clavien-Dindo classification26, 27.
Secondary outcomes
 Proportion of patients requiring blood transfusion
 Mean quantity of units of blood transfusion
 Mean operative blood loss in milliliters
 Mean length of hospital stay in days
 Mean length of intensive therapy unit (ITU) stay in days
 Mean operative time in minutes
5Data collection
The following data were independently extracted by two review authors from each study: first
author, year of publication, country, inclusion and exclusion criteria, participant characteristics,
number of participants with liver cirrhosis or liver steatosis, major or minor liver resections
performed, study design, and outcomes of interest described above. The risk of bias of the
included trials was assessed based on the following bias risk domains: allocation sequence
generation, allocation concealment, blinding of participants and personnel, blinding of
outcome assessors, incomplete outcome data, selective outcome reporting, and vested interest
bias. For each of these risk domains of bias the studies were categorized as low risk, uncertain
risk, and high risk of bias.
Statistical analysis
For binary outcomes the odds ratio (OR) was calculated, and for continuous outcomes the mean
difference (MD) was calculated. For each outcome of interest, Stata/IC 11 (StataCorp LP) was
used to draw a network plot of all the interventions assessed for that specific outcome. Any
interventions that were not connected to the other interventions through the network plot were
excluded from the analysis of that outcome. A Bayesian network meta-analysis was conducted
using the Markov chain Monte Carlo method in WinBUGS 1.4. The treatment contrast (OR for
binary outcomes, MD for continuous outcomes) for any two interventions was modelled as a
function of comparisons between each individual intervention and an arbitrarily selected
reference group28. The reference group was selected to be the surgery alone group.
The residual deviance and Deviance Information Criteria (DIC) were used for assessing
between study heterogeneity as per the guidance from the National Institute for Health and
Clinical Excellence (NICE) Decision Support Unit (DSU) documents29. Three different models
were run for each outcome: fixed-effect model, random-effects model, and random-effects
inconsistency model. The choice of the model was based on the model fit, and a lower DIC
indicated a better model fit29. Evidence of inconsistency between direct and indirect
comparisons was assessed by examining the geometry of the network diagrams and by
comparing the deviance and DIC statistics of the consistency and inconsistency models30. The
probability of ranking of an intervention for each outcome of interest was calculated.
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7RESULTS
Eligible studies
A total of 522 references were identified through electronic searches of CENTRAL (n=60),
MEDLINE (n=154), EMBASE (n=119), and Science Citation Index Expanded (n=189). Five
more references were identified for further assessment through scanning reference lists. The
study flow diagram is shown in Figure 1. After reviewing 75 full-text articles, 31 references
were excluded. Forty four RCTs met the inclusion criteria3, 7-21, 31-58 reporting on 2457
participants. The characteristics of the included trials are shown in Table 1. The risk of bias of
the trials is shown in Supplementary Figure 1.
Overall network meta-analysis
An overall network meta-analysis was performed to compare eight classes of active
interventions aimed at decreasing IR injury along with a control group which was surgery
alone. The classes of intervention were grouped based on their mechanism of action:
hypothermia, ischemic preconditioning, antioxidants, immunomodulators, cardiovascular
modulators, steroids, treatments that increase hepatic glycogen, and miscellaneous therapies
(Table 2). Statistically significant results are shown in Table 3. The classes of interventions
with the highest probability of ranking from best to worst for the outcomes of interest are
summarized in Table 4.
Mortality
The fixed-effect model was preferred for this outcome based on the DIC statistics, and there
was no evidence of inconsistency in the networks. The pairwise odds ratios of the different
treatment comparisons identified no significant difference in mortality between the different
groups. The network plot for mortality is shown in Figure 2.
8Serious adverse events
The fixed-effect model was used and there was no evidence of inconsistency. Significantly
fewer serious adverse events were found in the ischemic preconditioning and cardiovascular
modulators groups compared to surgery alone. There were significantly fewer serious adverse
events in the miscellaneous group compared to surgery alone, ischemic preconditioning,
immunomodulators, and steroids. There was no significant difference in the other comparisons.
Proportion of patients transfused
The fixed-effect model was preferred and there was no evidence of inconsistency. Pairwise
comparison of the interventions showed that significantly fewer people were transfused with
ischemic preconditioning compared to steroids. There was no significant difference in the other
comparisons.
Quantity of blood transfusion per patient
The random-effects model was used and there was no evidence of inconsistency. No evidence
of any significant difference in quantity of blood transfusion per patient between the different
interventions was found.
Operative blood loss
The fixed-effect model was used and there was no evidence of inconsistency. The pairwise
mean differences of the different group comparisons showed that ischemic preconditioning had
significantly lower operative blood loss compared to all other groups and ranked best treatment
with 99.7% probability. The surgery alone group had significantly lower operative blood loss
compared to all other groups except ischemic preconditioning. The steroids and increased
hepatic glycogen groups were found to have significantly lower operative blood loss compared
to the hypothermia, immunomodulators, and miscellaneous groups.
9Length of hospital stay
The random-effects model was preferred and there was no evidence of inconsistency. The
pairwise comparison of the interventions showed ischemic preconditioning to have
significantly shorter length of hospital stay compared to surgery alone by 2.3 days. There was
no significant difference in the other comparisons.
ITU stay
The random-effects model was preferred and there was no evidence of inconsistency. Pairwise
comparison of the groups showed no evidence of any significant difference in the ITU stay.
Operative time
The fixed-effect model was used and there was no evidence of inconsistency. The pairwise
mean differences of the different treatments showed ischemic preconditioning and increased
hepatic glycogen to have significantly shorter operative time compared to steroids by 17 and
26 minutes respectively. There was no significant difference in the operating time between the
other comparisons.
Sensitivity network meta-analysis – individual interventions
A sensitivity network meta-analysis was performed to compare all the individual interventions
included in each class of interventions aimed at decreasing IR injury. No significant difference
was found in mortality, quantity of blood transfusion per patient, and ITU stay, between the
different interventions. Ischemic preconditioning, sevoflurane, verapamil, and gabexate
mesilate had significantly fewer serious adverse events compared to surgery alone. Fewer
people were transfused with ischemic preconditioning compared to steroids.
10
Ischemic preconditioning was found to have significantly lower operative blood loss compared
to surgery alone. Ischemic preconditioning and surgery alone had lower operative blood loss
compared to hypothermia, prostaglandin E1, steroids, verapamil, S-adenosyl-L-methionine,
insulin, branched chain aminoacids, gabexate mesilate, and melatonin. Ischemic
preconditioning was found to have significantly shorter length of hospital stay compared to
surgery alone. Furthermore, ischemic preconditioning and pre-storing hepatocellular glycogen
were found to have significantly shorter operative time compared to steroids.
Sensitivity network meta-analysis – larger groups
A network meta-analysis was performed to compare the following 4 larger groups: surgery
alone, hypothermia, ischemic preconditioning, and all pharmacological interventions. There
was no significant difference in mortality, proportion of patients transfused, quantity of blood
transfusion per patient, ITU stay, and operative time, between the 4 groups. Ischemic
preconditioning and pharmacological interventions were found to have significantly fewer
serious adverse events compared to surgery alone.
Ischemic preconditioning had a high probability (87%) of being the best treatment for operating
time. Ischemic preconditioning had significantly lower operative blood loss compared to
surgery alone, hypothermia, and pharmacological interventions, and was confirmed best
treatment for operative blood loss with 100% probability. Surgery alone had significantly lower
operative blood loss compared to hypothermia and pharmacological interventions. Moreover,
ischemic preconditioning and pharmacological interventions resulted in significantly shorter
hospital stay compared to surgery alone.
Metaregression – cirrhotic livers
A metaregression was performed based on the percentage of cirrhotic livers included in each
trial. No significant difference was identified between the classes of interventions with regards
to mortality, proportion of patients transfused, quantity of blood transfused per patient,
operating time, hospital stay, and ITU stay. The ischemic preconditioning, antioxidants, and
miscellaneous groups had significantly fewer serious adverse events compared to the surgery
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alone group. The surgery alone, ischemic preconditioning, steroids, and increased hepatic
glycogen groups resulted in significantly lower operative blood loss compared to the
immunomodulators and miscellaneous groups of interventions. In addition, ischemic
preconditioning had significantly lower operative blood loss compared to surgery alone.
Metaregression – major liver resections
A metaregression was performed based on the percentage of major liver resections performed
in each trial. Major liver resection was defined as a right or left hemihepatectomy, or extended
hemihepatectomy, or resection of three or more liver segments according to Couinaud59. No
significant difference was identified between the classes of interventions with regards to
mortality, operating time, and ITU stay. Regarding serious adverse events, ischemic
preconditioning, cardiovascular modulators, and miscellaneous classes of interventions
resulted in significantly fewer serious adverse events compared to surgery alone. Ischemic
preconditioning had significantly lower operative blood loss compared to the surgery alone,
immunomodulators, cardiovascular modulators, steroids, and increased hepatic glycogen
groups. Finally, ischemic preconditioning resulted in significantly shorter length of hospital
stay and fewer patients needing blood transfusion compared to surgery alone.
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DISCUSSION
This network meta-analysis identified three groups of interventions – ischemic
preconditioning, cardiovascular modulators, miscellaneous group – which resulted in fewer
serious adverse events compared to the surgery alone group. Although there was a high
probability that the miscellaneous group of interventions was best for reducing serious adverse
events (74% chance), sensitivity analysis performed showed none of the individual
interventions within the miscellaneous group to have high probability of being the best
treatment for this outcome. Overall, no individual intervention had a probability higher than
40% of being best treatment for serious adverse events. Although sevoflurane, verapamil, and
gabexate mesilate were found to have fewer serious adverse events during sensitivity analysis,
none of these treatments significantly reduced ITU or hospital stay, which would be anticipated
if an intervention made a significant reduction in serious adverse events. On the other hand,
ischemic preconditioning, which resulted in fewer serious adverse events, showed multiple
additional clinical benefits including shorter hospital stay, shorter operative time, and
decreased blood loss.
The decreased operative time is perhaps counter-intuitive as ischemic preconditioning is an
additional operative manoeuver. However, ischemic preconditioning may decrease operative
time by decreasing the time taken for parenchymal transection because of reduced blood loss
during surgery, facilitating subsequent operative manoeuvers such as parenchymal dissection,
and by shortening the time necessary for hemostasis35, 60. Blood loss is one of the most
important factors affecting the peri-operative outcomes of patients undergoing liver resection61-
63. This study showed that ischemic preconditioning had significantly lower operative blood
loss compared to the surgery alone group and compared to all other interventions, and it had a
high probability of being the best treatment for this outcome.
Another important finding was that the surgery alone group had significantly lower operative
blood loss compared to all other interventions, except the ischemic preconditioning group.
Therefore, not only was ischemic preconditioning the only intervention to significantly reduce
blood loss, but also all other interventions resulted in significantly higher operative blood loss
compared to the surgery alone group. A possible explanation in the increase in operative blood
loss by the other interventions is that by increasing the microvascular flow and perfusion of the
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liver in order to decrease IR injury, they result in increased overall blood flow and blood loss
during hepatectomy. This apparent disadvantage in increasing blood loss of all other
interventions except ischemic preconditioning should be weighed against any apparent benefit
of these interventions, e.g. in reducing serious adverse events.
Trials in the literature demonstrated the beneficial effects of ischemic preconditioning on liver
resection surgery in patients with background healthy livers, as well as those with background
cirrhotic or steatotic livers, by showing a decrease in postoperative liver enzymes which are
markers for liver parenchymal injury3, 12, 13, 43, 64. Although liver parenchymal injury is
associated with derangements in the liver function tests (LFTs), this network meta-analysis did
not assess LFTs due to significant variation between the included trials in the way LFTs were
assessed. In particular, LFTs were reported at different time intervals, different methods of
measurement were used between trials, and different measurement scales were reported.
Perioperative outcomes, including adverse events, are thought to be clinically more relevant
and were compared in this study.
In all the trials included in this review where ischemic preconditioning was used to decrease
IR injury, ischemic preconditioning was performed with liver vascular inflow occlusion
(Pringle manoeuver). Nevertheless, there was variability between trials in the timing of
ischemic preconditioning and the type of vascular occlusion performed during liver resection.
In some trials, ischemic preconditioning was performed with 10 minutes of vascular inflow
occlusion and 10 minutes of reperfusion3, 12, 13, 49, 53, whereas in other trials ischemic
preconditioning was performed with 5 minutes of vascular inflow occlusion and 5 minutes of
reperfusion36, 43, 44. Furthermore, in some trials ischemic preconditioning was followed by
vascular inflow occlusion12, 13, 35, 46, 49, whereas in other trials it was followed by selective
hepatic vascular exclusion8, 9, 53. The downside of this is that it does not allow for the optimal
ischemic preconditioning protocol to be determined accurately, or even whether some
protocols were ineffective.
Other possible sources of bias in this network meta-analysis are the proportion of cirrhotic and
steatotic livers included in each trial, and the proportion of patients undergoing major liver
resections. Therefore, metaregressions were performed based on the proportion of cirrhotic
livers included and the proportion of major liver resections performed in each trial.
Unfortunately, due to the low number of trials (7 trials out of 44) reporting on the number of
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steatotic livers included, a metaregression based on the proportion of steatotic livers was not
possible. The results of the metaregression analyses based on cirrhotic livers and major
resections were similar to the overall network meta-analysis, showing no significant
differences between interventions with regards to mortality, proportion of patients transfused,
operating time, and ITU stay. Metaregression analysis confirmed the benefits of ischemic
preconditioning with regards to fewer serious adverse events and lower operative blood loss.
Additionally, the metaregression based on the proportion of major liver resections suggested
that ischemic preconditioning results in fewer patients needing blood transfusion and shorter
length of hospital stay.
The results of this network meta-analysis agree with the results of previous standard pairwise
meta-analyses, and would suggest multiple beneficial clinical end points to ischemic
preconditioning treatment, including reduced blood transfusion requirements and shorter
operative time, and no significant difference in other perioperative outcomes, such as mortality,
hospital stay, or ITU stay25, 60, 65. The previous standard pairwise meta-analyses25, 65 did not
demonstrate a significant decrease in serious adverse events or operative blood loss with
ischemic preconditioning as in this network meta-analysis, possibly due to a lower number of
participants or RCTs included. Through indirect comparisons, a network meta-analysis allows
more RCTs to be included in the analysis and more comparisons to be made between
interventions that have not been previously evaluated directly against each other. Ischemic
preconditioning, which can be achieved without any requirement for equipment, costs, or
additional expertise, demonstrated a high likelihood of being beneficial to the patients
undergoing liver resection. Further RCTs are needed to confirm clinical benefit in order to
allow ischemic preconditioning to become standard practice during liver resection.
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FIGURES AND TABLES
Figure 1: Study flow diagram.
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Figure 2: Network plot for mortality. Similar network plots were produced for each
outcome of interest. Footnotes: circles represent the intervention as a node in the network;
lines represent direct comparisons using RCTs; thickness of lines represents the number of
RCTs included in each comparison, also represented by the numbers.
22
Table 1: Summary of studies included, showing name of first author, year of publication, interventions compared, total number of patients
in each study, and the number with percentages of cirrhotic livers and major resections (NR=not reported).
Study Treatments compared Total
N
Cirrhotic
n (%)
Major
resections
Study Treatments compared Total
N
Cirrhotic
n (%)
Major
resections
Aldrighetti
2006
steroids vs
no steroids
73 26 (36) 53 (73) Li
2004b
ulinastatin vs
no ulinastatin
31 27 (87) NR
Arkadopoulos
2009
ischemic preconditioning vs
no ischemic preconditioning
84 0 (0) 84 (100) Liang
2002
ischemic preconditioning vs
no ischemic preconditioning
29 25 (86) NR
Azoulay
2006
ischemic preconditioning vs
no ischemic preconditioning
60 1 (2) 60 (100) Luo
2009
pre-storing glycogen vs
no pre-storing glycogen
38 19 (50) NR
Bartels
2004
vitamin E vs
placebo
47 0 (0) 33 (70) Marx
2000
dopexamine vs
dopamine
19 NR 19 (100)
Beck-Schimmer
2008
sevoflurane vs
no sevoflurane
64 0 (0) 28 (44) Muratore
2003
steroids vs
no steroids
53 16 (30) 28 (53)
Beck-Shimmer
2012
sevoflurane vs
no sevoflurane
65 0 (0) 26 (40) Nickkholgh
2011
melatonin vs
placebo
36 0 (0) 36 (100)
Cerwenka
1999
antioxidant multivitamin vs
no antioxidant multivitamin
50 13 (26) NR Nuzzo
2004
ischemic preconditioning vs
no ischemic preconditioning
42 0 (0) 14 (33)
Chouker
2004
ischemic preconditioning vs
no ischemic preconditioning
33 0 (0) 9 (27) Orii
2000
amrinone vs placebo vs
prostaglandin E1
45 45 (100) 0 (0)
Clavien
2003
ischemic preconditioning vs
no ischemic preconditioning
100 0 (0) 75 (75) Petrowsky
2006
ischemic preconditioning vs
no ischemic preconditioning
73 0 (0) 44 (60)
Hahn
2011
ischemic preconditioning vs
no ischemic preconditioning
160 60 (38) 117 (73) Petrowsky
2010
pentoxifylline vs
placebo
101 0 (0) 95 (94)
Hassanain
2013
insulin vs
no insulin
56 NR 17 (30) Scatton
2011
ischemic preconditioning vs
no ischemic preconditioning
84 0 (0) 78 (93)
Hayashi
2011
steroids vs
no steroids
200 NR 26 (13) Settaf
2001
trimetazidine vs
placebo
76 NR NR
Heizmann
2008
ischemic preconditioning vs
no ischemic preconditioning
61 0 (0) 19 (31) Shirabe
1996
OKY046 vs
no OKY 046
17 NR 9 (53)
Hou
2009
ischemic preconditioning vs
no ischemic preconditioning
48 24 (50) 16 (33) Smyrniotis
2006
ischemic preconditioning vs
no ischemic preconditioning
54 0 (0) 27 (50)
23
Ishikawa
2010
branched chain amino acids vs
no branched chain amino acids
24 10 (42) 5 (21) Su
2013
S-adenosyl-L-methionine vs
no S-adenosyl-L-methionine
79 79 (100) 33 (42)
Kawano
2005
prostaglandin E1 vs
no prostaglandin E1
22 NR NR Sugawara
1998
prostaglandin E1 vs
placebo
24 24 (100) 0 (0)
Kim
1996
hypothermia vs
no hypothermia
20 NR 18 (90) Tang
2007
hepatocellular glycogen vs
no hepatocellular glycogen
57 50 (88) 38 (67)
Kim
2002
gabexate mesilate vs
no gabexate mesilate
66 31 (47) 27 (41) Tsujii
2012
sivelestat vs
placebo
50 NR NR
Kim
2006
gabexate mesilate vs
no gabexate mesilate
60 40 (67) 51 (75) Vriens
2002
allopurinol vs
no allopurinol
16 0 (0) NR
Kostopanagiotou
2006
mannitol vs
placebo
30 NR 28 (93) Winbladh
2012
ischemic preconditioning vs
no ischemic preconditioning
32 NR 16 (50)
Laviolle
2012
propofol vs
desflurane
30 0 (0) 22 (73) Xia
2009
verapamil vs
no verapamil
86 86 (100) 51 (59)
Li
2004a
ischemic preconditioning vs
no ischemic preconditioning
29 29 (100) 4 (14) Yamashita
2001
steroids vs
no steroids
33 0 (0) 11 (33)
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Table 2: Types of network meta-analyses performed. Footnotes: An overall network meta-
analysis was performed to compare eight classes of active interventions aimed at decreasing
IR injury along with a control group which was surgery alone. The classes of intervention were
grouped based on their mechanism of action. A sensitivity network meta-analysis was
performed to compare all the individual interventions included in each class of intervention
aimed at decreasing IR injury. Another sensitivity network meta-analysis was performed to
compare the following 4 larger groups: surgery alone, hypothermia, ischemic preconditioning,
and all pharmacological interventions.
Overall network
meta-analysis
Sensitivity analysis
All interventions
Sensitivity analysis
Larger groups
Surgery alone Surgery alone Surgery alone
Hypothermia Hypothermia Hypothermia
Ischemic preconditioning Ischemic preconditioning Ischemic preconditioning
Antioxidants
Allopurinol
Pharmacological interventions
Antioxidant multivitamin
Mannitol
Melatonin
Propofol
Vitamin E
Cardiovascular modulators
Amrinone
Dopamine
Dopexamine
OKY 046
Trimetazidine
Verapamil
Immunomodulators
Gabexate mesilate
Pentoxifylline
Prostaglandin E1
Sivelestat
Increased hepatic glycogen Insulin
Pre-storing hepatocellular glycogen
Steroids Steroids
Miscellaneous
Branched chain amino acids
Desflurane
S-adenosyl-L-methionine
Sevoflurane
Ulinastatin
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Table 3: Statistically significant pairwise odds ratios (yellow treatment over blue treatment) and mean differences (yellow treatment minus
blue treatment) of the comparisons of the classes of interventions for all outcomes of interest. Footnotes: OR=odds ratio; MD=mean
difference; (95% credible intervals); NA=not applicable; NO=no statistically significant outcomes for this pairwise comparison; 1=serious adverse
events; 2=proportion of patients transfused, 3=operative blood loss, 4=length of hospital stay, 5=operative time. There was no statistically
significant difference between the interventions for the outcomes: mortality, quantity of blood transfusion per patient, and ITU stay.
CLASSES OF
INTERVENTIONS
Hypothermia Ischemic preconditioning Antioxidants Immunomodulators
Surgery alone MD 247.1 (143.59 to 350.61)3 OR 0.66 (0.44- 0.98)1
MD -35.97 (-53.76 to -18.18)3
MD -2.34 (-4.06 to -0.62)4
MD 207 (34.13 to 379.87)3 MD 231.2 (145.82 to 316.58)3
Hypothermia NA MD -283.07 (-388.09 to -178.05)3 NO NO
Ischemic
preconditioning
NA NA MD 242.97 (69.19 to 416.75)3 MD 267.17 (179.96 to 354.38)3
Antioxidants NA NA NA NO
Cardiovascular modulators Steroids Increased hepatic glycogen Miscellaneous
Surgery alone OR 0.39 (0.18-0.87)1
MD 142.2 (61.59 to 222.81)3
MD 69.32 (21.46 to 117.18)3 MD 92.04 (25.2 to 158.88)3 OR 0.21 (0.08-0.51)1
MD 209.7 (118.32 to 301.08)3
Hypothermia NO MD -177.78 (-291.82 to -63.74)3 MD -155.06 (-278.27 to -31.85)3 NO
Ischemic
preconditioning
MD 178.17 (95.62 to 260.72)3 OR 2.31 (1.03-5.18)2
MD 105.29 (54.23 to 156.35)3
MD 16.68 (0.79 to 32.57)5
MD 128.01 (58.85 to 197.17)3 OR 0.31 (0.12-0.85)1
MD 245.67 (152.58 to 338.76)3
Antioxidants NO NO NO NO
26
Immuno-
modulators
NO MD -161.88 (-259.76 to -64)3 MD -139.16 (-247.59 to -30.73)3 OR 0.31 (0.1-0.96)1
Cardiovascular
modulators
NA NO NO NO
Steroids NA NA MD -25.94 (-48.22 to -3.66)5 OR 0.31 (0.1-0.99)1
MD 140.38 (37.23 to 243.53)3
Increased hepatic
glycogen
NA NA NA MD 117.66 (4.45 to 230.87)3
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Table 4: Classes of interventions aiming to decrease hepatic IR injury with the highest probability of ranking from best to worst (1st to
9th) for the outcomes of interest. Footnotes: P=probability of ranking; NA=not applicable because less than 9 interventions were analyzed for
this outcome. Interventions not included in the analysis for this outcome: 1=hypothermia; 2=antioxidants, miscellaneous; 3=hypothermia,
cardiovascular modulators; 4=hypothermia, increased hepatic glycogen; 5=hypothermia, cardiovascular modulators, steroids, increased hepatic
glycogen, miscellaneous, 6=hypothermia.
OUTCOMES
RANKS
1st 2nd 3rd 4th 5th 6th 7th 8th 9th
Mortality Increased
hepatic glycogen
P=0.253
Immuno-
modulators
P=0.225
Immuno-
modulators
P=0.212
Ischemic
preconditioning
P=0.205
Surgery alone
P=0.231
Surgery alone
P=0.290
Surgery alone
P=0.221
Steroids
P=0.179
Hypothermia
P=0.292
Serious adverse
events
Miscellaneous
P=0.742
Cardiovascular
modulators
P=0.374
Cardiovascular
modulators
P=0.246
Ischemic
preconditioning
P=0.226
Ischemic
preconditioning
P=0.293
Ischemic
preconditioning
P=0.235
Surgery alone
P=0.404
Surgery alone
P=0.455
NA
1
Proportion of
patients transfused
Immuno-
modulators
P=0.424
Ischemic
preconditioning
P=0.395
Ischemic
preconditioning
P=0.272
Surgery alone
P=0.404
Surgery alone
P=0.280
Steroids
P=0.477
Hypothermia
P=0.665
NA
2
NA
Quantity of blood
transfusion
Steroids
P=0.318
Antioxidants
P=0.226
Antioxidants
P=0.198
Surgery alone
P=0.282
Surgery alone
P=0.317
Surgery alone
P=0.179
Miscellaneous
P=0.255
NA
3
NA
Operative blood
loss
Ischemic
preconditioning
P=0.997
Surgery alone
P=0.985
Steroids
P=0.451
Increased hepatic
glycogen
P=0.492
Cardiovascular
modulators
P=0.478
Miscellaneous
P=0.256
Miscellaneous
P=0.296
Immuno-
modulators
P=0.316
Hypothermia
P=0.388
Length of hospital
stay
Miscellaneous
P=0.324
Ischemic
preconditioning
P=0.268
Ischemic
preconditioning
P=0.297
Ischemic
preconditioning
P=0.208
Surgery alone
P=0.226
Surgery alone
P=0.425
Immuno-
modulators
P=0.294
NA
4
NA
ITU stay Immuno-
modulators
P=0.453
Ischemic
preconditioning
P=0.427
Surgery alone
P=0.427
Surgery alone
P=0.426
NA
5
NA NA NA NA
Operating time Increased
hepatic glycogen
P=0.430
Increased hepatic
glycogen
P=0.324
Ischemic
preconditioning
P=0.369
Surgery alone
P=0.341
Surgery alone
P=0.358
Steroids
P=0.343
Miscellaneous
P=0.343
Cardiovascular
modulators
P=0.465
NA
6
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Supplementary Figure 1: Risk of bias summary: review authors' judgments about each
risk of bias item for each included study. Footnotes: green plus sign = low risk of bias, yellow
question mark = unclear risk of bias, red minus sign = high risk of bias.
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Supplementary Table 1: Detailed search strategy.
Database Time span Search strategy
Cochrane Central Register of Controlled Trials
(CENTRAL) in The Cochrane Library (Wiley)
October 6th
2013
#1 (ischaemia OR ischaemia OR ischemic OR ischaemic OR reperfusion)
AND (injury OR injuries OR damage OR damages)
#2 MeSH descriptor Reperfusion Injury explode all trees
#3 (#1 OR #2)
#4 liver OR hepatic OR hepato*
#5 MeSH descriptor Liver explode all trees
#6 (#4 OR #5)
#7 resection OR resections OR segmentectomy OR segmentectomies
#8 (#6 AND #7)
#9 hepatectomy OR hepatectomies
#10 MeSH descriptor Hepatectomy explode all trees
#11 (#8 OR #9 OR #10)
#12 (#3 AND #11)
MEDLINE (Pubmed)
January
1947 to
October
2013
(((ischaemia OR ischaemia OR ischemic OR ischaemic OR reperfusion)
AND (injury OR injuries OR damage OR damages)) OR "Reperfusion
Injury"[Mesh])) AND (((liver OR hepatic OR hepato* OR "liver"[MeSH])
AND (resection OR resections OR segmentectomy OR segmentectomies))
OR hepatectomy OR hepatectomies OR "hepatectomy"[MeSH]) AND
((randomized controlled trial [pt] OR controlled clinical trial [pt] OR
randomized [tiab] OR placebo [tiab] OR drug therapy [sh] OR randomly
[tiab] OR trial [tiab] OR groups [tiab]) NOT (animals [mh] NOT humans
[mh]))
EMBASE (OvidSP)
January
1974 to
October
2013
1 (ischaemia or ischaemia or ischemic or ischaemic or reperfusion).af.
2 (injury or injuries or damage or damages).af.
3 1 and 2
4 exp Reperfusion Injury/
5 3 or 4
6 (liver or hepatic or hepato*).af.
30
7 (resection or resections or segmentectomy or segmentectomies).af.
8 6 and 7
9 (hepatectomy or hepatectomies).af.
10 exp Liver Resection/
11 8 or 9 or 10
12 5 and 11
13 exp crossover-procedure/ or exp double-blind procedure/ or exp
randomized controlled trial/ or single-blind procedure/
14 (random* OR factorial* OR crossover* OR cross over* OR cross-over*
OR placebo* OR double* adj blind* OR single* adj blind* OR assign* OR
allocat* OR volunteer*).af.
15 13 OR 14
16 12 AND 15
Science Citation Index Expanded
(http://www.webofknowledge.com/?DestApp=WOS)
January
1945 to
October
2013
#1 TS=((ischaemia OR ischaemia OR ischemic OR ischaemic OR
reperfusion) AND (injury OR injuries OR damage OR damages))
#2 TS=((liver OR hepatic OR hepato*) AND (resection OR resections OR
segmentectomy OR segmentectomies) OR hepatectomy OR hepatectomies)
#3 TS=(random* OR rct* OR crossover OR masked OR blind* OR
placebo* OR meta-analysis OR systematic review* OR meta-analys*)
#4 #1 AND #2 AND #3
